Normal skin contains an unexpectedly high number of cancer-associated mutations, according to a study published in Science. The findings illuminate the first steps cells take towards becoming a cancer and demonstrate the value of analysing normal tissue to learn more about the origins of the disease.
Drinking water or unsweetened tea or coffee in place of one sugary drink per day can reduce the risk of type 2 diabetes, according to research published today in the journal Diabetologia.
A test for a wide range of genetic risk factors could improve doctors’ ability to work out which women are at increased risk of developing breast cancer, a major study of more than 65,000 women has shown.
One of the world’s leading childhood brain tumour experts, Professor Richard Gilbertson, has been appointed as Li Ka Shing Chair of Oncology in Cambridge and Director of the Cambridge Cancer Centre. He will take up his appointment in August.
Scientists have discovered 15 previously unknown genetic ‘hot-spots’ that can increase a woman’s risk of developing breast cancer, according to research published today in Nature Genetics.
People who sleep for more than eight hours a day have an increased risk of stroke, according to a study by the University of Cambridge – and this risk doubles for older people who persistently sleep longer than average. However, the researchers say it is unclear why this association exists and call for further research to explore the link.
A clinical trial due to begin later this year will see scientists observing close up, in real time – and in patients – how tumours respond to new drugs.
The order in which genetic mutations are acquired determines how an individual cancer behaves, according to research from the University of Cambridge, published today in the New England Journal of Medicine.
Astronomy and oncology do not make obvious bedfellows, but the search for new stars and galaxies has surprising similarities with the search for cancerous cells. This has led to new ways of speeding up image analysis in cancer research.
A new drug for ovarian cancer, developed by researchers at the University of Cambridge and AstraZeneca, has today become the first of new class of drugs, known as PARP-inhibitors, to be granted approval anywhere in the world. The drug, Lynparza, has been granted Marketing Authorisation from the European Commission.
© 2025 University of Cambridge
